| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Citius Pharmaceuticals, Inc. | 78% | -1.5% | $79,920,034 | 66,049,615 | 0% | Citius Pharmaceuticals, Inc. | 10 Dec 2025 | |
| ARMISTICE CAPITAL, LLC | 9.8% | $15,582,099 | 7,675,911 | Armistice Capital, LLC | 30 Sep 2025 |
As of 30 Sep 2025, 16 institutional investors reported holding 8,357,159 shares of CITIUS ONCOLOGY, INC. - Common Shares, $0.0001 par value per share (CTOR). This represents 9.9% of the company’s total 84,787,696 outstanding shares.
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 1,500 | $1,500 | +$1,500 | $1.00 | 1 |
| 2025 Q3 | 8,357,159 | $16,966,429 | +$16,255,712 | $2.03 | 16 |
| 2025 Q2 | 227,492 | $989,589 | +$573,842 | $4.35 | 7 |
| 2025 Q1 | 105,008 | $97,657 | -$115,519 | $0.93 | 6 |
| 2024 Q4 | 200,884 | $230,191 | +$180,602 | $1.15 | 11 |
| 2024 Q3 | 41,238 | $57,016 | +$57,016 | $1.39 | 7 |